Raoudha Doghri1, Pascal Finetti2, Karima Mrad1,3, Maroua Manai4,3,2, Rihab Bouabsa1, Mohamed Manai3, Daniel Birnbaum2, François Bertucci2,5,6, Lamia Charfi1,3, Maha Driss1,3. 1. Anatomic Pathology Department, Salah Azaiez Institute, Tunis, Tunisia. 2. Department of Predictive Oncology, Cancer Research Center of Marseille, Aix Marseille University, Marseille, France. 3. Laboratory of Mycology, Pathologies and Biomarkers (LR16ES05), Biology Department, Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, Tunisia. 4. Anatomic Pathology Department, Salah Azaiez Institute, Tunis, Tunisia maroua.m@hotmail.com. 5. Training and Research Unit of Medicine, Aix Marseille University, Marseille, France. 6. Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
Abstract
BACKGROUND: Epithelial ovarian cancer (EOC) is the major gynecological cause of cancer deaths. Annexin A1 (ANXA1) protein has been implicated in the aggressiveness of several cancer types. MATERIALS AND METHODS: This study retrospectively assessed ANXA1 expression in epithelial cells of 156 pre-chemotherapy EOC samples and 34 normal ovarian samples from patients treated at Salah Azaiez Institute. Using immunohistochemistry, ANXA1 expression was compared in normal versus cancer samples; correlations with clinicopathological features, including overall survival, were sought. RESULTS: Fifty-two percent of tumor samples showed epithelial ANXA1 staining versus only 26% of normal samples (Fisher's exact test, p=0.00794). Epithelial ANXA1 expression was correlated with better overall survival in both univariate and multivariate analyses. CONCLUSION: The possible contribution of ANXA1 overexpression to EOC outcome may be relevant to therapeutic strategies. Copyright
BACKGROUND:Epithelial ovarian cancer (EOC) is the major gynecological cause of cancer deaths. Annexin A1 (ANXA1) protein has been implicated in the aggressiveness of several cancer types. MATERIALS AND METHODS: This study retrospectively assessed ANXA1 expression in epithelial cells of 156 pre-chemotherapy EOC samples and 34 normal ovarian samples from patients treated at Salah Azaiez Institute. Using immunohistochemistry, ANXA1 expression was compared in normal versus cancer samples; correlations with clinicopathological features, including overall survival, were sought. RESULTS: Fifty-two percent of tumor samples showed epithelial ANXA1 staining versus only 26% of normal samples (Fisher's exact test, p=0.00794). Epithelial ANXA1 expression was correlated with better overall survival in both univariate and multivariate analyses. CONCLUSION: The possible contribution of ANXA1 overexpression to EOC outcome may be relevant to therapeutic strategies. Copyright
Authors: Richard W Tothill; Anna V Tinker; Joshy George; Robert Brown; Stephen B Fox; Stephen Lade; Daryl S Johnson; Melanie K Trivett; Dariush Etemadmoghadam; Bianca Locandro; Nadia Traficante; Sian Fereday; Jillian A Hung; Yoke-Eng Chiew; Izhak Haviv; Dorota Gertig; Anna DeFazio; David D L Bowtell Journal: Clin Cancer Res Date: 2008-08-15 Impact factor: 12.531
Authors: Luxi Chen; Yi Yuan; Shreya Kar; Madhu M Kanchi; Suruchi Arora; Ji E Kim; Pei F Koh; Einas Yousef; Ramar P Samy; Muthu K Shanmugam; Tuan Z Tan; Sung W Shin; Frank Arfuso; Han M Shen; Henry Yang; Boon C Goh; Joo I Park; Louis Gaboury; Peter E Lobie; Gautam Sethi; Lina H K Lim; Alan P Kumar Journal: Mol Cancer Ther Date: 2017-08-15 Impact factor: 6.261
Authors: Sabine Maschler; Christoph A Gebeshuber; Eva-Maria Wiedemann; Memetcan Alacakaptan; Martin Schreiber; Ivana Custic; Hartmut Beug Journal: EMBO Mol Med Date: 2010-10 Impact factor: 12.137